Overview
overview
- Dr. Kyung Bo Kimâs research interests lie at the interface between chemistry and biology, primarily developing small molecules targeting the ubiquitin-proteasome pathway that can be used to unravel pathophysiological processes or treat human diseases. Specifically, Dr. Kimâs research is focused on the potential application of proteasome inhibitors for challenging, incurable disease states, such as neurodegenerative diseases (Alzheimerâs disease, Parkinsonâs disease, and age-related macular degeneration) and multiple myeloma (MM). Additional research interest is to develop immunoproteasome inhibitors (targeting the immunoproteasome catalytic subunits LMP2 and/or LMP7) with favorable pharmaceutical properties to treat chronic inflammatory disorders, such as inflammatory bowel disease (IBD) and other autoimmune diseases.
Publications
selected scholarly works & creative activities
-
Article
-
2025Hydroxylation near the epoxyketone of carfilzomib confers protection from microsomal epoxide hydrolase-mediated metabolism. Drug Metabolism And Disposition. 53.Full Text via DOI: 10.1016/j.dmd.2025.100115 Web of Science: 001540392600001
-
2024Brain-Permeable Immunoproteasome-Targeting Macrocyclic Peptide Epoxyketones for Alzheimer's Disease. Journal of Medicinal Chemistry. 67:7146-7157.Full Text via DOI: 10.1021/acs.jmedchem.3c02488 Web of Science: 001226319600001
-
2024Inhibition of Immunoproteasome Attenuates NLRP3 Inflammasome Response by Regulating E3 Ubiquitin Ligase TRIM31. Cells. 13.Full Text via DOI: 10.3390/cells13080675 Web of Science: 001210080000001
-
2024Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation. Journal of Pharmaceutical Sciences. 113:711-717.Full Text via DOI: 10.1016/j.xphs.2023.08.026 Web of Science: 001188632800001
-
2022The pharmaceutical potential of AR‐65, a novel Alzheimer’s disease drug targeting the immunoproteasome. Alzheimer's and Dementia. 18.Full Text via DOI: 10.1002/alz.064511
-
2022Inhibition of immunoproteasome attenuates NLRP3 inflammasome formation in tumor necrosis factor α-stimulated intestinal epithelial cell. Biochemical and Biophysical Research Communications. 624:157-163.Full Text via DOI: 10.1016/j.bbrc.2022.07.120 Web of Science: 000843961300001
-
2022Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib. Journal of Pharmaceutical Sciences. 111:1172-1177.Full Text via DOI: 10.1016/j.xphs.2021.09.022 Web of Science: 000820824100006
-
2021Alu complementary DNA is enriched in atrophic macular degeneration and triggers retinal pigmented epithelium toxicity via cytosolic innate immunity.. Science Advances. 7:eabj3658.Full Text via DOI: 10.1126/sciadv.abj3658
-
2021Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease. Journal of Medicinal Chemistry. 64:10934-10950.Full Text via DOI: 10.1021/acs.jmedchem.1c00291 Web of Science: 000685644300024
-
2021Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 118.Full Text via DOI: 10.1073/pnas.2022751118
-
2020Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib. Pharmaceutical Research. 37.Full Text via DOI: 10.1007/s11095-020-02922-9
-
2020Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction. Cancer Research. 80:3492-3506.Full Text via DOI: 10.1158/0008-5472.CAN-20-0246 Web of Science: 000567796800008
-
2020LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease. Journal of Medicinal Chemistry. 63:3763-3783.Full Text via DOI: 10.1021/acs.jmedchem.0c00416 Web of Science: 000526405300024
-
2020Prevalence, Predictors, and Psychosocial Mechanism of Cancer Information Avoidance: Findings from a National Survey of U.S. Adults. Health Communication. 35:322-330.Full Text via DOI: 10.1080/10410236.2018.1563028
-
2020Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells. American Journal of Transplantation. 20:399-410.Full Text via DOI: 10.1111/ajt.15634
-
2019A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer’s disease. Scientific Reports. 9.Full Text via DOI: 10.1038/s41598-019-54846-z
-
2019H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. Scientific Reports. 9.Full Text via DOI: 10.1038/s41598-019-40635-1
-
2019P4‐680: A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME ATTENUATES DISEASE PROGRESSION IN MOUSE MODELS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia. 15:p1592-p1592.Full Text via DOI: 10.1016/j.jalz.2019.09.045
-
2019Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib. Journal of Medicinal Chemistry. 62:4444-4455.Full Text via DOI: 10.1021/acs.jmedchem.8b01943 Web of Science: 000467781700012
-
2019Development of Epoxyketone‐based Immunoproteasome‐selective Inhibitors with Enhanced Brain Distribution In Vivo. The FASEB Journal. 33:670.19-670.19.Full Text via DOI: 10.1096/fasebj.2019.33.1_supplement.670.19
-
2019Examining the Effects of MTV’s 16 and Pregnant on Adolescent Girls’ Sexual Health: The Implications of Character Affinity, Pregnancy Risk Factors, and Health Literacy on Message Effectiveness. Health Communication. 34:180-190.Full Text via DOI: 10.1080/10410236.2017.1399506
-
2018Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine. Chemico-Biological Interactions. 293:107-114.Full Text via DOI: 10.1016/j.cbi.2018.08.002
-
2018Development of Fc-Fused Cocaine Hydrolase for Cocaine Addiction Treatment: Catalytic and Pharmacokinetic Properties. AAPS Journal. 20.Full Text via DOI: 10.1208/s12248-018-0214-9
-
2018CGAS drives noncanonical-inflammasome activation in age-related macular degeneration. Nature Medicine. 24:50-61.Full Text via DOI: 10.1038/nm.4450
-
2017When You Exercise Your Avatar in a Virtual Game: The Role of Avatars' Body Shape and Behavior in Users' Health Behavior. Interacting with computers. 29:455-466.Full Text via DOI: 10.1093/iwc/iwx003
-
2017Cancer Cells with De Novo or Acquired Resistance to Carfilzomib Remain Dependent on the Proteasome for Their Survival and Growth. The FASEB Journal. 31.Full Text via DOI: 10.1096/fasebj.31.1_supplement.1064.5
-
2017Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. PLoS ONE. 12.Full Text via DOI: 10.1371/journal.pone.0173247
-
2017Polymer micelle formulation of proteasome inhibitor carfilzomib as a potential strategy to improve metabolic stability and anti-cancer efficacy in human multiple myeloma and lung cancer. Drug Metabolism and Pharmacokinetics. 32:s46.Full Text via DOI: 10.1016/j.dmpk.2016.10.195
-
2016High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design. ChemBioChem. 17:2115-2117.Full Text via DOI: 10.1002/cbic.201600488
-
2016Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity. Therapeutic delivery. 7:665-681.Full Text via DOI: 10.4155/tde-2016-0041
-
2016Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4Rα overexpressed melanoma models. Oncotarget. 7:23425-23438.Full Text via DOI: 10.18632/oncotarget.8111
-
2015Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. Journal of Pharmacology and Experimental Therapeutics. 355:168-173.Full Text via DOI: 10.1124/jpet.115.226993
-
2015A cross-cultural comparison of cognitive and affective mediators in the relationship between media use and body image disturbance: focusing on US and Korean women. Asian Journal of Communication. 25:507-524.Full Text via DOI: 10.1080/01292986.2014.995681
-
2015Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. Journal of Medicinal Chemistry. 58:2036-2041.Full Text via DOI: 10.1021/jm501344n
-
2015Elucidating the catalytic subunit composition of distinct proteasome subtypes: A crosslinking approach employing bifunctional activity-based probes. ChemBioChem. 16:284-292.Full Text via DOI: 10.1002/cbic.201402491
-
2014Abstract 1707: Accelerated proteasome turnover as a potential mechanism of acquired resistance to carfilzomib in BxPC3 pancreatic cancer cells. Cancer Research. 74:1707-1707.Full Text via DOI: 10.1158/1538-7445.am2014-1707
-
2014Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening. Bioorganic and Medicinal Chemistry Letters. 24:3614-3617.Full Text via DOI: 10.1016/j.bmcl.2014.05.025
-
2014Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. Journal of Medicinal Chemistry. 57:6197-6209.Full Text via DOI: 10.1021/jm500716s
-
2014A FRET-based approach for identification of proteasome catalytic subunit composition. Molecular Biosystems. 10:196-200.Full Text via DOI: 10.1039/c3mb70471h
-
2014Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin. Pharmaceutical Research. 31:148-159.Full Text via DOI: 10.1007/s11095-013-1147-8
-
2014The immunoproteasome as a therapeutic target for hematological malignancies. Current Cancer Drug Targets. 14:537-548.Full Text via DOI: 10.2174/1568009614666140723113139
-
2013Activity-Based Imaging Probes of the Proteasome. Cell Biochemistry and Biophysics. 67:91-101.Full Text via DOI: 10.1007/s12013-013-9626-4
-
2013From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes. Natural product reports (Print). 30:600-604.Full Text via DOI: 10.1039/c3np20126k
-
2013Antiviral Efficacy of a Short PNA Targeting microRNA-122 Using Galactosylated Cationic Liposome as a Carrier for the Delivery of the PNA-DNA Hybrid to Hepatocytes. Bulletin of the Korean Chemical Society. 34:735-742.Full Text via DOI: 10.5012/bkcs.2013.34.3.735
-
2013A cancer-specific variant of the slco1b3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Molecular Pharmaceutics. 10:406-416.Full Text via DOI: 10.1021/mp3005353
-
2013Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochemical Pharmacology. 86:816-823.Full Text via DOI: 10.1016/j.bcp.2013.07.020
-
2012Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model. Carcinogenesis. 33:2520-2528.Full Text via DOI: 10.1093/carcin/bgs265
-
2012Implications and development of AHR-based therapeutic agents. Molecular and Cellular Pharmacology. 4:53-60.Full Text via DOI: 10.4255/mcpharmacol.12.05
-
2012Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells. ChemBioChem. 13:1899-1903.Full Text via DOI: 10.1002/cbic.201200307
-
2012Cover Picture: Activity‐Based Near‐Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells (ChemBioChem 13/2012). ChemBioChem. 13:1829-1829.Full Text via DOI: 10.1002/cbic.201290053
-
2012Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Molecular Biosystems. 8:2295-2302.Full Text via DOI: 10.1039/c2mb25125f
-
2012Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Molecular Pharmaceutics. 9:2197-2205.Full Text via DOI: 10.1021/mp300044b
-
2012Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2. Biochemical Journal. 445:377-382.Full Text via DOI: 10.1042/BJ20120820
-
2012A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. British Journal of Cancer. 107:53-62.Full Text via DOI: 10.1038/bjc.2012.243
-
2012PROTAC-induced proteolytic targeting. Methods in molecular biology (Clifton, N.J.). 832:627-638.Full Text via DOI: 10.1007/978-1-61779-474-2_44
-
2012A bright approach to the immunoproteasome: Development of LMP2/β1i-specific imaging probes. Bioorganic and Medicinal Chemistry. 20:607-613.Full Text via DOI: 10.1016/j.bmc.2011.06.039
-
2012Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin. Journal of Biological Chemistry. 287:989-1006.Full Text via DOI: 10.1074/jbc.M111.297150
-
2012Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor. Molecular Pharmacology. 81:3-11.Full Text via DOI: 10.1124/mol.111.073643
-
2011ChemInform Abstract: A Selective Solvent‐Free Self‐Condensation of Carbonyl Compounds Utilizing Microwave Irradiation.. ChemInform. 42:no-no.Full Text via DOI: 10.1002/chin.201143031
-
2011A selective solvent-free self-condensation of carbonyl compounds utilizing microwave irradiation. Green Chemistry. 13:1546-1549.Full Text via DOI: 10.1039/c1gc15164a
-
2011Abstract 2616: The immunoproteasome subunit LMP2 as a novel therapeutic target for non-small cell lung cancer. Cancer Research. 71:2616-2616.Full Text via DOI: 10.1158/1538-7445.am2011-2616
-
2011Impact of linker length on the activity of PROTACs. Molecular Biosystems. 7:359-364.Full Text via DOI: 10.1039/c0mb00074d
-
2011The immunoproteasome: An emerging therapeutic target. Current Topics in Medicinal Chemistry. 11:2923-2930.Full Text via DOI: 10.2174/156802611798281348
-
2010Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations. Journal of Physical Chemistry B. 114:12333-12339.Full Text via DOI: 10.1021/jp1058098
-
2010Two-headed PROTAC: An effective new tool for targeted protein degradation. ChemBioChem. 11:1531-1534.Full Text via DOI: 10.1002/cbic.201000222
-
2010Jostling for position: Optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem. 5:979-985.Full Text via DOI: 10.1002/cmdc.201000146
-
2010Targeted Degradation of Proteins by PROTACs.. Current Protocols in Chemical Biology. 2:71-87.Full Text via DOI: 10.1002/9780470559277.ch090242
-
2010Abstract 2631: Target validation of the LMP2 inhibitor, UK-101. Cancer Research. 70:2631-2631.Full Text via DOI: 10.1158/1538-7445.am10-2631
-
2009Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-κB activity via direct interaction with p50. Molecular Cancer Therapeutics. 8:1613-1624.Full Text via DOI: 10.1158/1535-7163.MCT-08-0694
-
2008Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene. 27:7201-7211.Full Text via DOI: 10.1038/onc.2008.320
-
2008ChemInform Abstract: Chemical Genetics: Exploring the Role of the Proteasome in Cell Biology Using Natural Products and Other Small Molecule Proteasome Inhibitors. ChemInform. 39:no-no.Full Text via DOI: 10.1002/chin.200829270
-
2008Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: A potential tool for chemoprevention. Molecular Pharmacology. 73:1064-1071.Full Text via DOI: 10.1124/mol.107.040840
-
2008Proteasome modulators: Essential chemical genetic tools for understanding human diseases. Molecular Biosystems. 4:280-286.Full Text via DOI: 10.1039/b716221a
-
2007Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: A useful chemical genetic tool. ChemBioChem. 8:2058-2062.Full Text via DOI: 10.1002/cbic.200700438
-
2007The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin. Chemistry and Biology. 14:623-634.Full Text via DOI: 10.1016/j.chembiol.2007.04.010
-
2007LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology. Chemistry and Biology. 14:419-430.Full Text via DOI: 10.1016/j.chembiol.2007.03.008
-
2006SAR studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor mechanisms. Bioorganic and Medicinal Chemistry Letters. 16:3383-3387.Full Text via DOI: 10.1016/j.bmcl.2006.04.030
-
2006Development of withaferin A analogs as probes of angiogenesis. Bioorganic and Medicinal Chemistry Letters. 16:2603-2607.Full Text via DOI: 10.1016/j.bmcl.2006.02.039
-
2005Towards immunoproteasome-specific inhibitors: An improved synthesis of dihydroeponemycin. European Journal of Organic Chemistry. 4829-4834.Full Text via DOI: 10.1002/ejoc.200500437
-
2005Use of PROTACS as molecular probes of angiogenesis. Bioorganic and Medicinal Chemistry Letters. 15:2724-2727.Full Text via DOI: 10.1016/j.bmcl.2005.04.008
-
2004Degradation of target protein in living cells by small-molecule proteolysis inducer. Bioorganic and Medicinal Chemistry Letters. 14:645-648.Full Text via DOI: 10.1016/j.bmcl.2003.11.042
-
2004Targeted degradation of proteins by small molecules: A novel tool for functional proteomics. Combinatorial Chemistry and High Throughput Screening. 7:689-697.Full Text via DOI: 10.2174/1386207043328364
-
2003Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.. Molecular & Cellular Proteomics. 2:1350-1358.Full Text via DOI: 10.1074/mcp.T300009-MCP200
-
2003Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. Journal of Clinical Investigation. 111:1771-1782.Full Text via DOI: 10.1172/JCI16198
-
2001ChemInform Abstract: The Ubiquitin‐Proteasome Pathway and Proteasome Inhibitors. ChemInform. 32:no-no.Full Text via DOI: 10.1002/chin.200136283
-
2001Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America. 98:8554-8559.Full Text via DOI: 10.1073/pnas.141230798
-
2001Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Molecular Cell. 7:411-420.Full Text via DOI: 10.1016/S1097-2765(01)00188-5
-
2000The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. Journal of Immunology. 164:6147-6157.Full Text via DOI: 10.4049/jimmunol.164.12.6147
-
2000On the conformation of UDP-Glc, a sugar nucleotide. Journal of the Chemical Society Perkin Transactions 2. 677-682.Full Text via DOI: 10.1039/a909389c
-
1999Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency. Bioorganic and Medicinal Chemistry Letters. 9:3335-3340.Full Text via DOI: 10.1016/s0960-894x(99)00612-5
-
1999ChemInform Abstract: Total Synthesis of the Potent Proteasome Inhibitor Epoxomicin: A Useful Tool for Understanding Proteasome Biology.. ChemInform. 30:no-no.Full Text via DOI: 10.1002/chin.199946187
-
1999Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology. Bioorganic and Medicinal Chemistry Letters. 9:2283-2288.Full Text via DOI: 10.1016/S0960-894X(99)00376-5
-
1999A new synthesis of symmetrical p1,p2-dinucleoside-5'-pyrophosphates. Nucleosides, Nucleotides and Nucleic Acids. 18:51-54.Full Text via DOI: 10.1080/07328319908045593
-
1999On the conformation of UDPG, a sugar nucleotide. Nucleosides, Nucleotides and Nucleic Acids. 18:1055-1056.Full Text via DOI: 10.1080/15257779908041643
-
1997Conversion of nucleosides to cyclic dinucleoside dipyrophosphates. Nucleosides, Nucleotides and Nucleic Acids. 16:81-85.Full Text via DOI: 10.1080/07328319708002523
-
1995A new synthesis of sucrose 6′-phosphate. Carbohydrate Research. 270:71-75.Full Text via DOI: 10.1016/0008-6215(94)00003-X
-
1994A new type of carboxypeptidase A inhibitor: Design, synthesis, and mechanistic implication. Pure and Applied Chemistry. 66:721-728.Full Text via DOI: 10.1351/pac199466040721
-
1991The function of S1′ subsite pocket of carboxypeptidase A. Bioorganic and Medicinal Chemistry Letters. 1:323-326.Full Text via DOI: 10.1016/S0960-894X(01)80817-9
-
1991The structural feature of S1′ subsite of carboxypeptidase A. Bioorganic and Medicinal Chemistry Letters. 1:317-322.Full Text via DOI: 10.1016/S0960-894X(01)80816-7
-
-
Book Chapter
-
2009Proteasome inhibitors recent progress and future directions. 99-119.Full Text via DOI: 10.1007/978-0-387-69147-3_7
-
2004Natural Product and Synthetic Proteasome Inhibitors. 47-63.Full Text via DOI: 10.1007/978-1-59259-794-9_4
-
Editorial Material
-
1991Design of a Novel Type of Zinc-Containing Protease Inhibitor. Journal of the American Chemical Society. 3200-3202.Full Text via DOI: 10.1021/ja00008a074
-
-
Letter
-
2000Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α',β'-epoxyketone proteasome inhibitors [12]. Journal of the American Chemical Society. 1237-1238.Full Text via DOI: 10.1021/ja993588m
-
-
Other Scholarly Work
-
2024Correction to "Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease".. Journal of Medicinal Chemistry. 5109-5110.Full Text via DOI: 10.1021/acs.jmedchem.4c00382
-
2015Dual effects of duplex RNA harboring 5'-terminal triphosphate on gene silencing and RIG-I mediated innate immune response.. Biochemical and Biophysical Research Communications. 591-597.Full Text via DOI: 10.1016/j.bbrc.2014.11.119
-
2012Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown.. Biomaterials. 2754-2761.Full Text via DOI: 10.1016/j.biomaterials.2011.12.015
-
20112,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV).. European Journal of Medicinal Chemistry. 5698-5704.Full Text via DOI: 10.1016/j.ejmech.2011.09.005
-
2010Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA.. Nucleic Acid Therapeutics. 285-296.Full Text via DOI: 10.1089/oli.2010.0256
-
1995A new synthesis of sucrose 6′-phosphate. Carbohydrate Research. C9.Full Text via DOI: 10.1016/0008-6215(95)00267-W
-
-
Preprint
-
Review
-
2021Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. Journal of Pharmaceutical Investigation. 483-502.Full Text via DOI: 10.1007/s40005-021-00532-0 Web of Science: 000648356800001
-
2021Proteasomal adaptations to FDA-approved proteasome inhibitors: A potential mechanism for drug resistance?. Cancer Drug Resistance. 634-645.Full Text via DOI: 10.20517/cdr.2021.27
-
2018Next-generation proteasome inhibitors for cancer therapy. Translational Research. 1-16.Full Text via DOI: 10.1016/j.trsl.2018.03.002
-
2013Inhibitors of the immunoproteasome: current status and future directions. Current Pharmaceutical Design. 4140-4151.Full Text via DOI: 10.2174/1381612811319220018
-
2008Chemical genetics: Exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. Journal of Medicinal Chemistry. 2600-2605.Full Text via DOI: 10.1021/jm070421s
-
2001The ubiquitin-proteasome pathway and proteasome inhibitors. Medicinal Research Reviews. 245-273.Full Text via DOI: 10.1002/med.1009
-
Research
principal investigator on
- Immunoproteasome Inhibitors for the Treatment of Alzheimer's Disease awarded by National Institute on Aging 2023 - 2026
- Development of proteasome inhibitors for the treatment of glioblastoma awarded by Baptist Health South Florida 2025 - 2026
Contact
full name
- Kyung Bo Kim
